The approach combines a blood measure of phosphorylated Tau 217 (p-tau217), a biomarker associated with Alzheimer’s disease, with age, sex and genetic risk to estimate a person’s future risk of cognitive impairment. Higher p-tau217 levels and older age were associated with greater risk.
“The goal is to provide a personalized estimate of the risk of developing cognitive impairment that is more meaningful than simply reporting whether a blood test is positive or negative for amyloid pathology,” says Alicia Algeciras-Schimnich, Ph.D., a Mayo Clinic laboratory medicine and pathology researcher and first author of the study.